

10/553,911



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 238 011 B1**

(12)

EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: 25.09.91 (51) Int. Cl.⁵: **C07H 19/044, A61K 31/70, C12P 19/38, //(C12P19/38, C12R1:465)**
- (21) Application number: 87103763.6
- (22) Date of filing: 16.03.87

(84) Polycyclic condensed amino sugar derivatives with anti-tumor and anti-bacterial activity, produced by streptomyces.

- (30) Priority: 20.03.86 JP 63704/86
- (42) Date of publication of application: 23.09.87 Bulletin 87/39
- (45) Publication of the grant of the patent: 25.09.91 Bulletin 91/39
- (84) Designated Contracting States: **DE FR GB IT**
- (56) References cited: **US-A- 4 524 145**

JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, no. 18, 20th September 1978, pages 800-801; A. FURUSAKI et al.: "X-Ray crystal structure of staurosporine: a new alkaloid from a streptomyces strain"

- (73) Proprietor: **KYOWA HAKKO KOGYO CO., LTD.**
6-1, Ohte-Machi Itchome
Chiyoda-ku Tokyo(JP)
- (72) Inventor: **Nomoto, Hisayo, c/o KYOWA HAKKO KOGYO CO., LTD**
6-1 Othemachi Itchome
Chiyoda-ku, Tokyo(JP)
Inventor: **Nakano, Hirofumi c/o KYOWA HAKKO KOGYO CO., LTD**
6-1 Othemachi Itchome
Chiyoda-ku Tokyo(JP)
Inventor: **Takahashi, Isami c/o KYOWA HAKKO KOGYO CO., LTD**
6-1 Othemachi Itchome
Chiyoda-ku Tokyo(JP)
Inventor: **Tamaoki, Tatsuya c/o KYOWA HAKKO KOGYO CO., LTD**
6-1 Othemachi Itchome
Chiyoda-ku Tokyo(JP)

EP 0 238 011 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

EP 0 238 011 B1

Inventor: Tomita, Fusao c/o KYOWA HAKKO
KOGYO CO.,LTD
6-1 Othemachi Itchome
Chiyoda-ku Tokyo(JP)
Inventor: Kawamoto, Isao c/o KYOWA HAKKO
KOGYO CO.,LTD
6-1 Othemachi Itchome
Chiyoda-ku Tokyo(JP)
Inventor: Asano, Kozo c/o KYOWA HAKKO
KOGYO CO.,LTD
6-1 Othemachi Itchome
Chiyoda-ku Tokyo(JP)
Inventor: Morimoto, Makoto,c/o KYOWA
HAKKO KOGYO CO.,LTD
6-1 Othemachi Itchome
Chiyoda-ku,Tokyo(JP)

⑦ Representative: Jacobacci, Filippo et al
c/o JACOBACCI-CASSETTA & PERANI S.n.c.
Via Alfieri, 17
I-10121 Torino(IT)

Description

Background of the Invention

The present invention relates to UCN-01 and a process for production thereof. UCN-01 has an anti-tumor activity and an anti-bacterial activity and is useful as an anti-tumor agent, a bactericide, etc.

The present inventors have made screening of microorganisms producing a substance with a useful pharmacological activity and have found that a microorganism belonging to the genus *Streptomyces* isolated from the soil in Tsuno-gun, Yamaguchi Prefecture, produces a substance having an anti-tumor activity and an anti-bacterial activity. As a result of further investigations, the present inventors have successfully isolated and purified an active substance UCN-01 and have confirmed from its physicochemical properties that UCN-01 is a novel substance, and thus the present invention has been established.

Staurosporine, which is structurally analogous to UCN-01, is described in J. C. S. Chem. Comm., pp.800 - 801 (1978). UCN-01 has a superior anti-tumor activity as compared with staurosporine.

Summary of the Invention

The novel substance UCN-01 having an anti-tumor activity and an anti-bacterial activity is specified by the following physicochemical properties:

- (a) Molecular formula: $C_{28}H_{25}N_4O_4$
- (b) Melting point: 245 - 250 °C (decomposed)
- (c) UV absorption spectrum: shown in Figure 1 (measured in MeOH)
- (d) IR absorption spectrum: shown in Figure 2 measured by the KBr method
- (e) Optical rotation: $[\alpha]_D^{22} + 132.0^\circ$ (c=0.3, MeOH)

(f) Solubility:

Soluble in methanol, chloroform, and dimethylsulfoxide, but scarcely soluble in water and hexane


(g) $^1\text{H-NMR}$ spectrum (measured in CDCl_3 , internal standard TMS)

$\delta(\text{ppm})$: 9.3(1H, d), 8.5(1H, d), 7.9(1H, d), 7.5-7.2(6H, m), 6.8(1H, s), 6.5(2H, d), 3.9(1H, d), 3.4(3H, s), 3.3(1H, d), 2.7-2.8(1H, m), 2.4(1H, m), 2.3(3H, s), 2.0-1.7(1H, br), 1.6(3H, s)

(h) $^{13}\text{C-NMR}$ spectrum (measured in CDCl_3 , internal standard TMS)

$\delta(\text{ppm})$: 171.5, 140.2, 137.2, 132.9, 131.2, 128.1, 126.5, 125.5, 124.8, 123.8, 123.2, 123.0, 120.2, 120.1, 117.5, 115.2, 115.1, 115.0, 107.1, 91.2, 84.1, 80.2, 79.5, 57.4, 50.6, 33.4, 30.2, 29.7

From the foregoing physicochemical properties, the structural formula of UCN-01 is determined to be as follows:



UCN-01 can be prepared by culturing a UCN-01-producing strain belonging to the genus *Streptomyces*.

Brief Description of the Drawings

Figure 1 shows UV absorption spectrum of UCN-01.

Figure 2 shows IR absorption spectrum of UCN-01.

Detailed Description of the Invention

UCN-01 can be obtained by culturing in a medium the microorganism Streptomyces sp UCN-01 (FERM BP-990), and recovering UCN-01 from the culture liquor.

5 UCN-01 strain has been isolated from the soil in Tsuno-gun, Yamaguchi Prefecture.

Morphological characteristics, physiological properties and growth conditions in various agar media of UCN-01 strain are shown in Tables 1 to 3, respectively.

Table 1

Morphology

Aerial mycelium: It is branched but not
fragmented.

Substrate mycelium: It is branched but not
fragmented.

Spore: Chains of more than 20 spores are
formed at the end of simply branched
aerial mycelium; it is spiral to open
spiral.

Shape and size of spore: Smooth, oval to cylindri-
cal, 0.5 to 0.7 x 0.7 to 1.0 μ m

Motility of spore: Negative

Color

Aerial mycelium: Extremely pale purplish grey
or white

Substrate mycelium: Colorless or beige, brown or
chocolate color.

Soluble pigment: Yellow to brownish orange

Chemical Composition

Cell wall amino acid: LL-diaminopimelic acid,
glycine, alanine, glutamic
acid.

Table 2

1) Assimilation of carbon sources

<u>5</u>	<u>Carbon Source</u>	<u>Growth</u>
	D-Glucose	++
	L-Arabinose	-
10	D-Xylose	-
	Inositol	-
	D-Mannitol	-
15	D-Fructose	-
	L-Rhamnose	-
20	Sucrose	-
	Raffinose	-
	Melibiose	-
25	Erythritol	-
	Mannose	-
	D-Ribose	+
30	Adonitol	-
	Glycerol	+
35		
40		
45		
50		
55		

EP 0 238 011 B1

	Lactose	-
5	Methylglucoside	-
	D-Galactose	-
	Starch	+
10	2) Liquefaction of gelatin:	Positive
	3) Hydrolysis of starch:	Positive
15	4) Coagulation and peptonization of defatted milk:	Both positive
	5) Formation of melanin-like pigment:	Positive
20	6) Growth temperature range (optimum):	20 to 32°C (28 to 30°C)
25	7) Salt resistance:	Grow at NaCl concentration up to 3%

Note 1) - : no growth
 + : moderate growth
 ++ : good growth

Note 2) Growth temperature range indicates the results obtained by observation for 2 days. The action on defatted milk and cellulose indicates the results obtained by observation for 1 month. With respect to the other items, the results obtained by observation for 2 weeks at 28°C are shown.

Table 3

	<u>Medium</u>	<u>Growth Condition</u>
5	Sucrose-nitrate agar medium	G: extremely poor AM: scant, cloud pink(7cb) SM: colorless P: negative
10	Glucose-asparagine agar medium	G: good AM: abundant, white(a) to light mustard tan(2ie) to down blue (15dc) SM: light wheat(2ea) P: negative
15	Glycerine-asparagine agar medium	G: moderate AM: fair, white(a) SM: light amber(3ic) P: pale honey gold
20	Starch agar medium	G: good AM: abundant, orchid haze(10dc) SM: light tan(3gc) P: negative
25	Tyrosine agar medium	G: moderate AM: scant to fair, orchid haze (10dc) SM: chocolate(5nl) P: pale chocolate
30	Nutrient agar medium	G: moderate AM: abundant, pearl(3ba) to dark covert gray(2ih) SM: gold(2lc) P: extremely pale yellow
35	Yeast extract - malt extract agar medium	G: moderate AM: abundant, orchid mist(10cb) to dusk(10fe) SM: bamboo(2gc) to yellow maple (3ng) P: extremely pale yellow
40	Oatmeal agar medium	G: moderate AM: fair, orchid tint(10ba) SM: colorless P: golden brown(3pi)
45	Peptone-yeast extract-iron agar medium	G: moderate AM: scant, white(a) SM: colorless P: adobe brown(3lg)
50		
55		

Hickey-Tresner
agar medium

G: good
AM: abundant, white(a) to orchid
mist(10cb)
SM: chestnut brown(4ni)
P: negative

Note 1) Culture: 28°C, 21 days

Note 2) Color indication: Color Harmony Manual,
Container Corporation of America

Note 3) G: growth

AM: formation of aerial mycelium and its
color

SM: color of substrate mycelium

P: soluble pigment

In addition to alanine and glutamic acid, LL-diaminopimelic acid and glycine were detected as cell wall amino acids, and the composition of cell wall was identified to be I type in chemical classification of Actinomycetales. Morphologically, it formed aerial mycelium simply branched and formed long spore chains at the end. Therefore, this strain was classified to the genus *Streptomyces* in Actinomycetales.

A strain having bacteriological properties akin to those of UCN-01 strain was searched for in the approved bacterial species, but no approved bacterial species identified to be the same as UCN-01 strain was found.

UCN-01 strain was named *Streptomyces* sp. UCN-01 and has been deposited with the Fermentation Research Institute, Agency of Industrial Science and Technology under FERM BP-990 on February 20, 1986.

As the medium for culturing in the present invention, either a natural medium or a synthetic medium can be used so long as it appropriately contains carbon sources, nitrogen sources, inorganic materials, etc.

As the carbon source, glucose, starch, glycerol, mannose, fructose, sucrose, molasses, alcohols such as methanol and ethanol, organic acids such as acetic acid, formic acid, citric acid and malic acid, etc. can be used.

As the nitrogen source, ammonium chloride, ammonium sulfate, ammonium nitrate, sodium nitrate, urea, peptone, meat extract, yeast extract, dry yeast, corn steep liquor, soybean powder, Casamino acid, etc. can be used.

As the inorganic materials, sodium chloride, potassium chloride, ferrous sulfate, manganese sulfate, copper sulfate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, magnesium phosphate, magnesium sulfate, calcium carbonate, etc. can be used.

In addition, substances for accelerating production of UCN-01, for example, biotin, vitamins, etc. can also be supplemented to the medium.

Culturing is usually carried out by liquid culture, and most preferably by submerged stirring culture. Culturing temperature is 25 to 32°C, preferably 28 to 30°C. It is desirable to maintain the pH of the medium at 4 to 10, preferably 6 to 8 by adding aqueous ammonia or aqueous ammonium carbonate during the culturing. Usually, by liquid culture for 1 to 7 days, the desired product is produced and accumulated in the culture liquor. When the amount of the product in the culture liquor reaches the maximum, culturing is discontinued.

The desired product is isolated and purified from the culture liquor after the microbial cells have been removed by filtration.

For the isolation and purification of UCN-01 from the culture liquor, the ordinary method for isolating a microbial metabolite from its culture liquor can be utilized. For example, the culture liquor is separated into the culture filtrate and the microbial cells. The microbial cells are extracted with a solvent such as chloroform, acetone, etc., and the extract is concentrated under reduced pressure to remove the solvent therefrom. The residue is dissolved in water. The cell-free culture filtrate and the aqueous solution are passed through a column packed with a non-ionic porous resin, for example, HP-20 (manufactured by Mitsubishi Chemical Industries Ltd.) to adsorb the active component. Then, the adsorbed active component

is eluted with methanol, acetone, etc. The eluate is concentrated to dryness, and water of pH 9 to 10 and ethyl acetate are added to the residue, followed by shaking, whereby the active component is shifted to the ethyl acetate layer. The lower aqueous layer is removed and then water of pH 2.5 is added thereto, followed by shaking, whereby the active component is shifted to the aqueous layer. Such a shift and dissolution operation is repeated several times and the active component is finally shifted to the ethyl acetate layer. The active component is dried to give a crude product. The thus obtained crude UCN-01 powder can be further purified by procedures such as recrystallization and various kinds of chromatography using Sephadex, silica gel, etc.

The biological properties of UCN-01 are shown below.

(A) Anti-bacterial activity

The minimum inhibitory concentration (MIC) against various microorganisms is shown below.

Table 4

	<u>Microorganism</u>	<u>MIC (μg/ml)</u>
20	Staphylococcus aureus ATCC 6538P	83
	Bacillus subtilis No. 10707	> 100
25	Klebsiella pneumoniae ATCC 10031	83
	Escherichia coli ATCC 26	83
30	Shigella sonnei ATCC 9290	100
	Salmonella typhi ATCC 9992	83

The anti-bacterial activity was measured by the agar dilution method, using a medium (pH 7) prepared by dissolving 3 g of Bacto-Tryptone[®] (manufactured by Difco Co., Ltd.), 3 g of meat extract, 1 g of yeast extract, 1 g of glucose and 16 g of agar in 1 l of water.

(B) Acute toxicity

The acute toxicity value (LD₅₀) was 30 mg/kg by intraperitoneal administration to mice.

(C) Anti-tumor activity

Therapeutic effect on lymphocytic leukemia P388 tumor:

Five male CDF₁ mice each having a weight of about 22 g were used for each group as test animals, and 1×10^6 cells of lymphocytic leukemia P388 tumor were implanted intraperitoneally in the test animals. 24 hours after implantation, 0.2 ml of a phosphate buffer saline (hereafter referred to as PBS) containing UCN-01 was intraperitoneally administered.

The composition of PBS was 0.8% NaCl, 0.02% KCl, 1.15% Na₂HPO₄, 5% K₂HPO₄ and 0.02% KH₂PO₄ (pH 7.0).


For comparison, 0.2 ml of PBS solution containing Staurosporine was intraperitoneally administered 24 hours after the implantation of the tumor cells. Increased life span (T/C) (T: mean survival days of the treated group, C: mean survival days of the control group) is shown in Table 5.

Table 5

6	<u>Compound</u>	<u>Dose</u> <u>(mg/kg)</u>	<u>Increased Life</u> <u>Span (T/C)</u>
	UCN-01	0 (control)	-
		7.5	1.12
10		15	1.24
		30	toxic
15	Staurosporine	1	1.10
		2	1.12
20		4	1.08

Notes: 1) LD₅₀ of Staurosporine is 6.6 mg/kg.

2) Staurosporine is described in J. C.S. Chem. Comm., pp. 800 - 801 (1978) and its structural formula is shown below.



UCN-01 has an anti-tumor activity and an anti-bacterial activity and is useful as an anti-tumor agent, a bactericide, etc.

The dose of UCN-01 to be administered to a human being is 0.01 - 20 mg/kg/day.

UCN-01 may be administered in the form of tablets, capsules, powder, granules, suppository, injection, etc. prepared in the ordinary manner, depending on the administration form.

For example, in the case of tablets, capsules, powder, granules and suppository, UCN-01 may be contained in an amount of 0.1 - 85% by weight. As other components (carriers), commonly employed excipients such as glucose, lactose, Avicel®, etc., disintegrators such as starch, calcium carboxymethylcellulose, etc., lubricants such as magnesium stearate, talc, etc., binders such as polyvinyl alcohol, gelatin, etc., and the like may be employed.

In the case of injection, UCN-01 may be contained in an amount of 0.05 - 50 mg / 2 - 50 ml. An injection

solution can be prepared using a carrier such as physiological saline, glucose solution, lactose solution or mannitol solution.

Certain specific embodiments of the present invention are illustrated by the following examples.

5 Example 1

Streptomyces sp. UCN-01 strain was used as a seed strain. The strain was inoculated in 300 ml of a seed medium (pH 7.2, prior to sterilization) containing 10 g/l Bacto-Tryptone (manufactured by Difco Co., Ltd.), 5 g/l yeast extract, 5 g/l NaCl and 1 g/l glucose in a 2 l-Erlenmeyer flask and subjected to shaking culture (200 rpm) at 30 °C for 48 hours. The resulting seed culture was inoculated in 15 l of a fermentation medium having the following composition in a 30 l-jar fermenter, and cultured at 30 °C for 72 hours with aeration and stirring (rotation: 250 rpm, aeration: 15 l/min).

Composition of the fermentation medium:

20 g/l glucose, 15 g/l soybean powder, 4 g/l calcium carbonate (pH 7.0, adjusted with NaOH prior to sterilization)

The pH of the medium was adjusted to 6.5 - 7.5 with aqueous ammonia during the culturing.

The microbial cells were separated from the culture liquor by filtration to give 13 l of a filtrate. Then, 13 l of the filtrate was passed through a column filled with 2 l of nonionic porous resin HP-20 (trademark, manufactured by Mitsubishi Chemical Industries Ltd.) to adsorb the active component. After washing with water, the column was further washed with 50% methanol to remove impurities, followed by elution with methanol. The eluted fraction was concentrated and adjusted to pH 10, followed by extraction with ethyl acetate. The ethyl acetate layer was transferred to 0.1N HCl and then the pH was adjusted to 10, followed by extraction with ethyl acetate. The extract was concentrated and developed with chloroform-methanol using silica gel (Wakogel® C-200; Wako Junyaku) to give an active component. Then, the active component was developed with chloroform-methanol using silica gel (Lichroprep® Si60, Merck) to give 5 mg of UCN-01. This fraction was dissolved in a small quantity of methanol. The solution was subjected to density gradient elution using high pressure liquid chromatography (Wakogel LC ODS 30K, Wako Junyaku) with 50% methanol and 100% methanol to give pure UCN-01. The thus obtained UCN-01 showed the physicochemical properties and biological properties described hereinbefore.

30 Example 2 (Injection)

2.0 g of UCN-01 was dissolved in 20 l of ethanol, and the solution was filtered through a Millipore® filter (pore diameter of 0.22 µ under pressure to effect sterilization). The resulting sterilized filtrate was charged in brown vials in 5.0 ml portions and freeze-dried in a conventional manner to give a freeze-dried product of 0.5 mg/vial.

Example 3 (Tablet)


40 Tablets were prepared from 180 mg of UCN-01, 90 mg of lactose, 40 mg of corn starch, 4 mg of polyvinyl alcohol, 28 mg of Avicel and 1 mg of magnesium stearate.

Claims

45 1. UCN-01 represented by the following formula:

50


55



2. A process for producing UCN-01 which comprises culturing in a medium the microorganism *Streptomyces* sp. UCN-01 (FERM BP-990) having the ability to produce UCN-01, accumulating UCN-01 in the culture liquor, and recovering UCN-01 therefrom.
3. A pharmaceutical composition comprising a pharmaceutical carrier and as an active ingredient, an effective amount of UCN-01.
4. A biologically pure culture of *Streptomyces* sp. UCN-01 (FERM BP-990) which possesses an ability to produce UCN-01.

Revendications


1. Substance UCN-01, représentée par la formule suivante:



2. Procédé de production d'UCN-01, qui comporte la culture, dans un milieu, du microorganisme *Streptomyces* sp. UCN-01 (FERM BP-990) possédant la capacité de produire UCN-01, l'accumulation de l'UCN-01 dans le bouillon de culture, et la récupération de l'UCN-01 à partir de celui-ci.
3. Composition pharmaceutique comprenant un véhicule pharmaceutique et, comme ingrédient actif, une quantité efficace d'UCN-01.
4. Culture biologiquement pure de *Streptomyces* sp. UCN-01 (FERM BP-990) qui possède la capacité de produire UCN-01.

Patentansprüche

1. UCN-01, verkörpert durch die folgende Formel:



2. Verfahren zur Herstellung von UCN-01, umfassend das Züchten des Mikroorganismus Streptomyces sp. UCN-01 (FERM BP-990), der zur Herstellung von UCN-01 befähigt ist, in einem Medium, Konzentrieren von UCN-01 in der Kulturlösung und Isolierung von UCN-01 daraus.
3. Arzneimittel, umfassend einen pharmazeutischen Träger und als Wirkstoff eine wirksame Menge von UCN-01.
4. Biologisch reine Kultur von Streptomyces sp. UCN-01 (FERM BP-990), die zur Herstellung von UCN-01 befähigt ist.

FIG. 1




FIG.2

